Thermo Fishr Sci Stock Price, News & Analysis

Thermo Fisher Scientific has expanded its Applied Biosystems portfolio with the new SeqStudio Flex Series Genetic Analyzer, aimed at enhancing clinical research and scientific discovery in areas like gene editing and infectious diseases. This mid-throughput genetic analyzer boasts increased plate capacity, simplified workflows, and advanced Wi-Fi connectivity for remote monitoring. Celebrating 40 years of the Applied Biosystems brand, Thermo Fisher emphasizes ongoing investments in capillary electrophoresis technology, which is central to its sequencing portfolio.

Thermo Fisher Scientific has announced a multiyear partnership with Medidata Acorn AI to develop PPD TrueCast, an advanced platform for enhancing clinical trial performance.

This application integrates machine learning and predictive analytics, leveraging data from over 40,000 trial sites and 50,000 investigators. It aims to optimize site selection, trial enrollment, and study cycle times, potentially reducing Phase III study enrollment by 1.5 months and improving milestone forecasting accuracy by 30%.

Thermo Fisher Scientific has launched the Renvo Rapid PCR Test, a rapid environmental testing solution for detecting SARS-CoV-2 pathogens in air samples. This test provides results in just 30 minutes, significantly faster than previous 4-24 hour methods. Designed for communal spaces like schools and healthcare facilities, it enhances indoor air monitoring for COVID-19. Utilizing proprietary Oscar PCR technology, this test strengthens risk mitigation efforts in public areas.

Thermo Fisher Scientific (TMO) reported strong financial results for Q4 and full-year 2021. Q4 revenue hit $10.70 billion, with diluted EPS at $4.17 and adjusted EPS at $6.54. For the full year, revenue surged 22% to $39.21 billion, with GAAP EPS increasing 22% to $19.46. The company achieved $9.23 billion in COVID-19 response revenue and invested $2.5 billion to enhance capacity. In acquisitions, TMO deployed $24 billion, including PPD, Inc., and PeproTech, while committing to net-zero carbon emissions by 2050.

Thermo Fisher Scientific (NYSE:TMO) has completed its acquisition of PeproTech for approximately $1.85 billion on December 30, 2021. PeproTech specializes in recombinant proteins such as cytokines and growth factors, which are integral to cell and gene therapy development. This acquisition enhances Thermo Fisher's biosciences portfolio, allowing for improved offerings to pharma and biotech clients. CEO Marc Casper highlighted that the integration will leverage existing capabilities and foster growth in the expanding cell therapy market.

Thermo Fisher Scientific (NYSE: TMO), a leader in scientific services, will have CEO Marc N. Casper present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 8:15 a.m. (EST). The presentation will cover the company's business outlook and future financial expectations. Thermo Fisher reported annual revenues of approximately $40 billion and employs over 100,000 people globally. Investors can access the webcast via the company's website.

Thermo Fisher Scientific (NYSE: TMO) announced the release of its fourth quarter and full year 2021 financial results on February 2, 2022, before market opening. The earnings call will take place at 8:30 a.m. EST on the same day. Investors can listen in via phone or the company's website. Thermo Fisher is a leader in the science sector with annual revenues around $40 billion. The company aims to support customers in various fields, including life sciences and diagnostics, with an extensive range of innovative technologies and services.

Thermo Fisher Scientific (NYSE: TMO), a leader in serving science, announced that Marc N. Casper, its CEO, will present at the 2022 Goldman Healthcare CEOs Unscripted Conference on January 6, 2022, at 9:00 a.m. EDT. This virtual event will highlight the company's initiatives in the healthcare sector. With an annual revenue of approximately $40 billion, Thermo Fisher supports various industries, including life sciences and diagnostics, through its innovative technologies and services. For more details, visit thermofisher.com.

Thermo Fisher Scientific has finalized its acquisition of PPD, Inc. for $17.4 billion, enhancing its position in the biopharma and biotech sectors. The acquisition is expected to add $1.50 to Thermo Fisher's adjusted earnings per share in 2022 and generate approximately $125 million in total synergies within three years. With this integration, Thermo Fisher expands its service offerings across clinical development, covering scientific discovery to drug manufacturing. PPD's stock has ceased trading on Nasdaq as it becomes part of Thermo Fisher's Laboratory Products and Services Segment.